SKK
TPST icon

Shepherd Kaplan Krochuk’s Tempest Therapeutics TPST Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-7
Closed -$28K – 273
2017
Q4 		$28K Sell
7
-4
-36% -$16.8K 0.02% 244
2017
Q3 		$45K Buy
11
+6
+120% +$25.6K 0.04% 205
2017
Q2 		$24K Sell
5
-7
-58% -$29.6K 0.01% 242
2017
Q1 		$65K Buy
+12
New +$55.9K 0.03% 234

Other funds holding TPST

SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
GC
GMT Capital Atlanta, Georgia $2.19B AUM 72.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TS
Third Security Radford, Virginia $241M AUM 45.43% 1-Year Est. Return

Shepherd Kaplan Krochuk's TPST Position: Q1 2018 in Review

Shepherd Kaplan Krochuk sold out of Tempest Therapeutics (TPST) in Q1 2018, closing a stake of 7 shares — an estimated $28K sold.

Shepherd Kaplan Krochuk first reported a position in TPST in Q1 2017 and held it in 4 quarters. The position peaked at $65K in Q1 2017. 41 funds tracked by Wall St. Rank hold TPST as of Q1 2018.

  • Shepherd Kaplan Krochuk reported no remaining Tempest Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 7 Tempest Therapeutics shares in Q1 2018, an estimated $28K.
  • Shepherd Kaplan Krochuk first reported a position in Tempest Therapeutics in Q1 2017 and held it in 4 quarters.
  • Shepherd Kaplan Krochuk's Tempest Therapeutics position peaked at $65K in Q1 2017.
  • 41 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2018.

Based on Shepherd Kaplan Krochuk's 13F filing for Q1 2018, filed 11 May 2018.